Trial: 201906169

Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects with Metastatic Colorectal Cancer

Phase

I/II

Principal Investigator

Trikalinos, Nikolaos

Disease Site

Colon; Rectum

Learn more about this study at: clinicaltrials.gov